Claro Advisors LLC Has $515,000 Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Claro Advisors LLC lifted its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTXFree Report) by 4.6% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,265 shares of the pharmaceutical company’s stock after acquiring an additional 56 shares during the period. Claro Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $515,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of VRTX. OFI Invest Asset Management acquired a new position in shares of Vertex Pharmaceuticals during the 3rd quarter valued at $25,000. ST Germain D J Co. Inc. acquired a new position in shares of Vertex Pharmaceuticals during the 2nd quarter valued at $26,000. Compass Wealth Management LLC acquired a new position in shares of Vertex Pharmaceuticals during the 4th quarter valued at $29,000. Fortitude Family Office LLC acquired a new position in Vertex Pharmaceuticals during the fourth quarter worth $30,000. Finally, Cornerstone Planning Group LLC acquired a new position in Vertex Pharmaceuticals during the second quarter worth $33,000. Institutional investors and hedge funds own 90.96% of the company’s stock.

Insiders Place Their Bets

In other Vertex Pharmaceuticals news, Chairman Jeffrey M. Leiden sold 6,648 shares of the stock in a transaction dated Monday, January 8th. The shares were sold at an average price of $419.07, for a total transaction of $2,785,977.36. Following the completion of the transaction, the chairman now owns 2,423 shares in the company, valued at $1,015,406.61. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Vertex Pharmaceuticals news, Chairman Jeffrey M. Leiden sold 6,648 shares of the stock in a transaction dated Monday, January 8th. The shares were sold at an average price of $419.07, for a total transaction of $2,785,977.36. Following the completion of the transaction, the chairman now owns 2,423 shares in the company, valued at $1,015,406.61. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Amit Sachdev sold 3,222 shares of the stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $420.24, for a total transaction of $1,354,013.28. Following the completion of the sale, the executive vice president now directly owns 74,364 shares in the company, valued at $31,250,727.36. The disclosure for this sale can be found here. Insiders sold 19,029 shares of company stock worth $7,989,227 over the last quarter. 0.30% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research firms have weighed in on VRTX. Maxim Group downgraded shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, January 31st. JPMorgan Chase & Co. upped their price objective on shares of Vertex Pharmaceuticals from $390.00 to $438.00 and gave the stock an “overweight” rating in a report on Thursday, February 1st. Canaccord Genuity Group downgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “sell” rating and upped their price objective for the stock from $332.00 to $379.00 in a report on Wednesday, January 24th. William Blair restated an “outperform” rating on shares of Vertex Pharmaceuticals in a report on Tuesday, February 6th. Finally, HC Wainwright upped their target price on shares of Vertex Pharmaceuticals from $397.00 to $457.00 and gave the stock a “buy” rating in a research note on Tuesday, February 6th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $420.48.

Check Out Our Latest Stock Report on Vertex Pharmaceuticals

Vertex Pharmaceuticals Price Performance

VRTX opened at $420.48 on Tuesday. The firm has a market cap of $108.61 billion, a P/E ratio of 30.27, a PEG ratio of 2.28 and a beta of 0.35. The firm has a 50-day moving average of $422.13 and a 200 day moving average of $392.37. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.78 and a current ratio of 3.99. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $313.47 and a fifty-two week high of $448.40.

Vertex Pharmaceuticals (NASDAQ:VRTXGet Free Report) last posted its quarterly earnings results on Monday, February 5th. The pharmaceutical company reported $4.20 earnings per share for the quarter, beating the consensus estimate of $3.85 by $0.35. The company had revenue of $2.52 billion during the quarter, compared to analyst estimates of $2.50 billion. Vertex Pharmaceuticals had a net margin of 36.68% and a return on equity of 21.91%. During the same quarter in the prior year, the business earned $3.33 earnings per share. On average, research analysts expect that Vertex Pharmaceuticals Incorporated will post 14.95 EPS for the current year.

Vertex Pharmaceuticals Company Profile

(Free Report)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Featured Articles

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.